Welcome to our dedicated page for Artivion news (Ticker: AORT), a resource for investors and traders seeking the latest updates and insights on Artivion stock.
Artivion, Inc. (NYSE: AORT) is a medical device company focused on cardiac and vascular surgery, particularly the treatment of aortic diseases. News about Artivion frequently centers on its aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, as well as clinical and regulatory developments related to these products.
Investors and clinicians following AORT news can expect regular updates on quarterly financial results, including revenue trends for key product lines such as stent grafts, On-X valves, BioGlue surgical sealant and preservation services. Earnings releases often discuss constant currency growth, adjusted EBITDA and non-GAAP performance metrics, along with management’s commentary on business momentum and financial outlook.
Artivion’s news flow also highlights progress in its aortic disease clinical programs. Recent announcements have covered the PERSEVERE and PROTECT trials for the AMDS Hybrid Prosthesis, including late-breaking data presented at major cardiothoracic surgery meetings, as well as the ARTIZEN pivotal trial evaluating the Arcevo LSA Hybrid Stent Graft System for acute and chronic aortic arch pathologies. These updates provide insight into the clinical performance and potential regulatory pathways for the company’s aortic technologies.
Additional news items may include participation in healthcare and medtech investor conferences, amendments to credit facilities, real estate transactions related to manufacturing capacity, and executive leadership changes disclosed through SEC filings and press releases. For market participants tracking AORT, this news page offers a centralized view of Artivion’s financial communications, clinical milestones and corporate developments over time.
Artivion (NYSE:AORT) reported strong Q2 2025 financial results with revenue reaching $113.0 million, marking a 15% increase from Q2 2024. The company achieved net income of $1.3 million ($0.03 per share) and non-GAAP net income of $10.7 million ($0.24 per share).
Key highlights include 33% growth in Adjusted EBITDA to $24.8 million, significant revenue growth across product lines with On-X and stent grafts both up 24%, and the exchange of $99.5 million in convertible senior notes for common stock. The company received FDA IDE approval for the ARTIZEN pivotal trial for Arcevo LSA.
Given strong performance, Artivion raised its 2025 guidance, now expecting constant currency growth of 12-14% with revenues between $435-443 million and adjusted EBITDA growth of 21-28% ($86-91 million).
Artivion (NYSE:AORT), a cardiac and vascular surgery company, announced its participation in two upcoming investor conferences. The company will present at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, at 10:30 a.m. ET, with a live webcast available on their website. Additionally, management will participate in investor meetings at the 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 12, 2025, though no webcast will be available for this event.
Artivion (NYSE: AORT), a cardiac and vascular surgery company specializing in aortic disease, has scheduled its second quarter 2025 financial results release for Thursday, August 7, 2025, after market close.
The company will host a teleconference call and live webcast at 4:30 p.m. ET featuring CEO Pat Mackin, followed by a Q&A session. Participants can dial 862-298-0702 to join the call, with replay available at 877-660-6853 or 201-612-7415 using conference number 13754541.
The webcast and earnings press release will be accessible through the Investors section of www.artivion.com.
Artivion (NYSE: AORT) has successfully closed transactions to exchange approximately $99.54 million of its 4.250% Convertible Senior Notes due 2025 for 4,334,347 shares of common stock. The company also made a cash payment of $1.7 million for accrued and unpaid interest to the note holders. Following these transactions, only $0.46 million in aggregate principal amount of the Notes remains outstanding.
CEO Pat Mackin emphasized that this effective retirement of convertible notes represents a significant milestone in strengthening Artivion's financial position, reducing leverage ratios, and enhancing balance sheet flexibility. J. Wood Capital Advisors LLC served as financial advisor for these exchange transactions.
Artivion (NYSE: AORT) has scheduled the release of its first quarter 2025 financial results for Monday, May 5, 2025, after market close. The cardiac and vascular surgery company will host a teleconference call and live webcast at 4:30 p.m. ET on the same day.
The earnings discussion will feature a Q&A session led by Pat Mackin, Chairman, President and CEO. Interested parties can join the teleconference by dialing 201-689-8261 before 4:30 p.m. ET. A replay will be available at 877-660-6853 or 201-612-7415 (conference number: 13752340). The webcast and replay can be accessed through the Investors section at www.artivion.com under Webcasts & Presentations.
Artivion (NYSE: AORT), a cardiac and vascular surgery company specializing in aortic disease, has announced its participation in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference. The company will engage in a virtual fireside chat on March 18, 2025 at 10:40 a.m. ET.
Investors and interested parties can access the live webcast through the Investors page on Artivion's website (www.artivion.com). The recorded session will remain available for replay on the website for 90 days following the event.